You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》交銀國際升科倫博泰生物(06990.HK)目標價至507元 評級「買入」
交銀國際發表研究報告指,科倫博泰生物-B(06990.HK)上半年銷售表現符合預期,蘆康沙妥珠市場滲透快速提升。該行認爲,隨着蘆康沙妥珠已獲批適應症的逐步放量,疊加新適應症持續拓展、合作夥伴默沙東(MRK.US)穩步推進海外開發,故上調其中國銷售高峯至57億元人民幣,同時早期管線的差異化競爭潛力在臨牀研究中逐步體現。 該行又指,管理層預計下半年蘆康沙妥珠將強勁增長,並維持全年銷售額8億至10億元人民幣的指引。該行指,公司上半年經調整淨虧損爲6,990萬元人民幣,該行估算剔除合作收入後的經營性虧損有所收窄。 交銀國際指,集團核心品種快速放量,大適應症和早期管線開發漸入佳境,略微上調科倫博泰2025年至2027年收入預測、上調長期高峯銷售預測,以反映蘆康沙妥珠及早期管線品種研發如期推進對產品銷售確定性的提升作用。該行表示,將目標價上調至507元,維持評級爲「買入」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account